Company Curis, Inc. Nasdaq
Equities
US2312691015
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Discovery and Development of Innovative Drug
100.0
%
| 10 | 100.0 % | 10 | 100.0 % | -1.37% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 10 | 100.0 % | 10 | 100.0 % | -1.37% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James Dentzer
CEO | Chief Executive Officer | 57 | 16-03-28 |
Diantha Duvall
DFI | Director of Finance/CFO | 52 | 22-07-25 |
Chief Tech/Sci/R&D Officer | - | 22-01-02 | |
Chief Tech/Sci/R&D Officer | - | 19-08-12 | |
Robert Martell
CTO | Chief Tech/Sci/R&D Officer | 61 | 11-08-31 |
Mark W. Noel
CTO | Chief Tech/Sci/R&D Officer | 65 | 01-02-28 |
Rachel Blasbalg
HRO | Human Resources Officer | - | 03-12-31 |
Dora Ferrari
PRN | Corporate Officer/Principal | - | 21-01-02 |
Nancy Soohoo
LAW | General Counsel | - | 02-12-31 |
Jonathan Zung
PRN | Corporate Officer/Principal | 59 | 23-04-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Kenneth Kaitin
BRD | Director/Board Member | 71 | 03-10-31 |
Martyn Greenacre
CHM | Chairman | 82 | 00-02-13 |
James Dentzer
CEO | Chief Executive Officer | 57 | 16-03-28 |
Marc Rubin
BRD | Director/Board Member | 69 | 10-06-02 |
Robert Martell
CTO | Chief Tech/Sci/R&D Officer | 61 | 11-08-31 |
Anne Borgman
BRD | Director/Board Member | 56 | 22-09-30 |
John Hohneker
BRD | Director/Board Member | 64 | 21-12-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,894,085 | 5,883,204 ( 99.82 %) | 0 | 99.82 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+29.91% | 48.16B | |
-0.77% | 41.73B | |
+43.29% | 41.03B | |
-5.31% | 28.77B | |
+10.64% | 25.59B | |
-21.37% | 18.96B | |
+7.96% | 12.92B | |
+27.25% | 12.03B | |
-3.74% | 11.77B |